190 related articles for article (PubMed ID: 8323333)
1. Short term correction of anaemia with recombinant human erythropoietin and reduction of cardiac output in end stage renal failure.
Morris KP; Skinner JR; Hunter S; Coulthard MG
Arch Dis Child; 1993 May; 68(5):644-8. PubMed ID: 8323333
[TBL] [Abstract][Full Text] [Related]
2. Non-cardiac benefits of human recombinant erythropoietin in end stage renal failure and anaemia.
Morris KP; Sharp J; Watson S; Coulthard MG
Arch Dis Child; 1993 Nov; 69(5):580-6. PubMed ID: 8257180
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular abnormalities in end stage renal failure: the effect of anaemia or uraemia?
Morris KP; Skinner JR; Hunter S; Coulthard MG
Arch Dis Child; 1994 Aug; 71(2):119-22. PubMed ID: 7944530
[TBL] [Abstract][Full Text] [Related]
4. [An echocardiographic study of the left ventricular functional indices in pediatric patients on hemodialysis and in treatment with recombinant human erythropoietin (r-HuEPO)].
Seracini D; Pollini I; Lavoratti GC; Pela I; Materassi M; Danti D; De Simone L; Favilli S; Manetti A
Pediatr Med Chir; 1994; 16(4):389-92. PubMed ID: 7816703
[TBL] [Abstract][Full Text] [Related]
5. The effect of recombinant human erythropoietin (r-HuEPO) on left ventricular mass and left ventricular hemodynamics in hemodialysis patients.
Minagawa T; Hirano T; Takada N; Ishiguro M; Ohtsuka H
Nihon Jinzo Gakkai Shi; 1994 Aug; 36(8):934-41. PubMed ID: 7933670
[TBL] [Abstract][Full Text] [Related]
6. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system.
Radermacher J; Koch KM
Clin Nephrol; 1995 Nov; 44 Suppl 1():S56-60. PubMed ID: 8608665
[TBL] [Abstract][Full Text] [Related]
7. Cardiac abnormalities in end stage renal failure and anaemia.
Morris KP; Skinner JR; Wren C; Hunter S; Coulthard MG
Arch Dis Child; 1993 May; 68(5):637-43. PubMed ID: 8323332
[TBL] [Abstract][Full Text] [Related]
8. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters.
Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652
[TBL] [Abstract][Full Text] [Related]
9. [Diastolic dysfunction in different types of left ventricular hypertrophy in patients with end-stage renal failure: impact of long-term erythropoietin therapy].
Dzgoeva FU; Gatagonova TM; Kadzaeva ZK; Khamitsaeva OV; Kochisova ZKh; Dzueva AT; Bazaeva BG; Bestaeva TL
Ter Arkh; 2013; 85(6):44-50. PubMed ID: 23866598
[TBL] [Abstract][Full Text] [Related]
10. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients.
Massimetti C; Pontillo D; Feriozzi S; Costantini S; Capezzuto A; Ancarani E
Blood Purif; 1998; 16(6):317-24. PubMed ID: 10343078
[TBL] [Abstract][Full Text] [Related]
11. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients.
Frank H; Heusser K; Höffken B; Huber P; Schmieder RE; Schobel HP
Kidney Int; 2004 Aug; 66(2):832-40. PubMed ID: 15253740
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
Frenken LA; Verberckmoes R; Michielsen P; Koene RA
Nephrol Dial Transplant; 1989; 4(9):782-6. PubMed ID: 2516609
[TBL] [Abstract][Full Text] [Related]
13. Haemodynamic changes and exercise tolerance in dialysis patients treated with erythropoietin.
Jurić M; Rupcić V; Topuzović N; Jakić M; Brlosić R; Rusić A; Karner I; Stipanić S; Kes P
Nephrol Dial Transplant; 1995; 10(8):1398-404. PubMed ID: 8538932
[TBL] [Abstract][Full Text] [Related]
14. Morphologic and functional changes of left ventricle in dialyzed patients after treatment with recombinant human erythropoietin (r-HuEPO).
Jeren-Struji'c B; Raos V; Jeren T; Horvatin-Godler S
Angiology; 2000 Feb; 51(2):131-9. PubMed ID: 10701721
[TBL] [Abstract][Full Text] [Related]
15. Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients.
Zehnder C; Zuber M; Sulzer M; Meyer B; Straumann E; Jenzer HR; Blumberg A
Nephron; 1992; 61(1):21-5. PubMed ID: 1388250
[TBL] [Abstract][Full Text] [Related]
16. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients.
Abraham PA; Opsahl JA; Rachael KM; Asinger R; Halstenson CE
Am J Nephrol; 1990; 10(2):128-36. PubMed ID: 2349956
[TBL] [Abstract][Full Text] [Related]
17. A study of recombinant human erythropoietin in the treatment of anaemia of chronic renal failure in children on haemodialysis.
Van Damme-Lombaerts R; Broyer M; Businger J; Baldauf C; Stocker H
Pediatr Nephrol; 1994 Jun; 8(3):338-42. PubMed ID: 7917862
[TBL] [Abstract][Full Text] [Related]
18. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients.
Cannella G; La Canna G; Sandrini M; Gaggiotti M; Nordio G; Movilli E; Maiorca R
Clin Nephrol; 1990 Dec; 34(6):272-8. PubMed ID: 2073771
[TBL] [Abstract][Full Text] [Related]
19. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin.
Silberberg J; Racine N; Barre P; Sniderman AD
Can J Cardiol; 1990; 6(1):1-4. PubMed ID: 2138048
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular consequences of renal anaemia and erythropoietin therapy.
Eckardt KU
Nephrol Dial Transplant; 1999 May; 14(5):1317-23. PubMed ID: 10344393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
